Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Cobenfy
Pharma
BMS delays key Cobenfy, milvexian readouts amid Q2 beat
BMS lifted its full-year outlook after recording nearly $13 billion in Q2 revenue, which topped Wall Street’s consensus by 10.6%.
Angus Liu
Jul 30, 2026 10:12am
BMS maintains Camzyos confidence amid Cytokinetics competition
Apr 30, 2026 2:20pm
BMS turns focus to new growth drivers as legacy meds decline
Feb 5, 2026 11:45am
Bristol Myers CEO pledges to 'cast a broad net' in dealmaking
Jan 12, 2026 4:28pm
BMS' Cobenfy TV ad is latest target of FDA untitled letter spree
Dec 19, 2025 10:44am
With site 'irregularities,' BMS delays key Cobenfy readout
Dec 3, 2025 10:14am
